Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + verteporfin
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal, Intravenous
01
Overview
Bevacizumab + verteporfin is a combination therapy used primarily in ophthalmology for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability. Verteporfin is a photosensitizer used in photodynamic therapy (PDT); upon activation by light, it generates reactive oxygen species that damage abnormal blood vessels. The combination leverages the antiangiogenic effect of bevacizumab with the vessel-targeting action of PDT, aiming to improve visual outcomes, reduce retreatment rates, and decrease injection frequency compared to monotherapy[1][2][3][5].
- Brand names
- Visudyne + Avastin
- Other names
- bevacizumab plus verteporfinintravitreal bevacizumab and photodynamic therapy with verteporfin
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on bevacizumab + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + verteporfin.